Home » Healthcare » Japan Artificial Intelligence AI in Medical Diagnostics Market

Japan AI in Medical Diagnostics Market By Component (Software, Services, Hardware [Processors {MPU, GPU, FPGA, ASIC}, Memory, Networks {Adapters, Switches, Interconnects}]); By Application (In Vivo Diagnostics [By Specialty {Radiology, Cardiology, Neurology, Obstetrics/Gynecology, Ophthalmology, Other Specialties}, By Modality {Computed Tomography, X-Ray, Magnetic Resonance Imaging, Ultrasound, Other Modalities}], In Vitro Diagnostics); By End User (Hospitals, Diagnostics Imaging Centers, Diagnostics Laboratories, Other End User); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $1999

Published: | Report ID: 38197 | Report Format : PDF
Historical Period  2019-2022
Base Year  2023
Forecast Period  2024-2032
Japan (AI) in medical diagnostics Market Size 2023  USD 97.91231 Million
Japan (AI) in medical diagnostics Market, CAGR  18.97%
Japan (AI) in medical diagnostics Market Size 2032  USD 473.81 Million

Market Overview:

Japan’s Artificial Intelligence (AI) in medical diagnostics market is on a promising trajectory, anticipated to reach USD 473.81 million by 2032, reflecting a significant compound annual growth rate (CAGR) of 18.97%.

The Japanese healthcare landscape is witnessing a transformative shift with the integration of AI-powered diagnostic solutions. Driven by the rising demand for early and accurate disease detection, coupled with government support and initiatives, AI technologies are increasingly being embraced as valuable tools. This trend is further fueled by Japan’s aging population and the subsequent need for efficient healthcare solutions. Technological advancements in AI algorithms and machine learning are enhancing the reliability and sophistication of diagnostic tools, empowering both established players like Fujifilm, Toshiba, and NEC Corporation, as well as emerging startups founded by medical professionals. While the market is primarily concentrated in major cities, increasing awareness and government initiatives are paving the way for broader adoption across Japan’s healthcare ecosystem.

As AI diagnostics gain momentum, several trends and challenges shape the market landscape. Automation of routine diagnostic tasks, specialization in disease areas, integration with electronic health records, and the adoption of cloud-based solutions are prominent trends driving market growth. However, regulatory hurdles, data security and privacy concerns, and reimbursement challenges pose significant considerations that need to be addressed for the widespread adoption of AI-powered diagnostic solutions in Japan’s healthcare sector.

Market Drivers:

Supportive Government Initiatives:

The Japanese government plays a pivotal role in driving the integration of AI technologies into healthcare through various supportive initiatives. For instance, the government has funded a major national initiative to develop data-driven artificial intelligence (AI) and internet of things (IoT) technologies that will increase the efficiency and quality of healthcare delivery. By providing funding for research grants and facilitating collaboration between healthcare institutions and technology companies, the government fosters an environment conducive to innovation. They have formed collaborations with industry and academic institutions to develop ten AI-enhanced hospitals by fiscal year 2022. Moreover, streamlining regulatory pathways for AI-based medical devices enables faster adoption and implementation of these technologies in diagnostic workflows. The government’s practical approach to AI-based medical devices has led to the creation of a roadmap for their realization and a five-year program in which industry, academia, and government work together.

Addressing Radiologist Shortages:

Japan’s healthcare system grapples with a shortage of radiologists, necessitating solutions to alleviate workload pressures and improve diagnostic efficiency. As an example, a 2018 study showed that if other staff weren’t picking up some of the slack, the potential workload for radiologists in Japan would be 2.8–4.2 times higher than in other countries. To complete all CT and MRI reports, at least 2.09 times more full-time diagnostic radiologists are needed in Japan. AI-powered diagnostic tools offer a promising solution by automating repetitive tasks, analyzing vast datasets of medical images, and flagging potential abnormalities. This automation frees up radiologists to focus on more complex cases, enhancing patient care and diagnostic accuracy.

Rising Demand for Personalized Medicine:

Advancements in AI enable the development of more precise and personalized diagnostic tools, catering to the growing demand for personalized medicine.By analyzing a patient’s medical history, genetic data, and imaging results, AI algorithms can provide comprehensive insights into their health status. This facilitates earlier disease detection, enabling timely interventions and potentially improving treatment outcomes. AI’s role, termed “augmented intelligence” by the American Medical Association, is enhancing healthcare through improved diagnostics, personalized medicine, patient engagement, and breaking down data silos, revolutionizing patient care and treatment decisions.For example, FPT Software used AI’s predictive analytics to detect pneumothorax and kidney tumors. When AI helps a doctor to predict a patient’s risk of developing certain conditions, healthcare changes from a reactive model to a proactive one. Identifying at-risk patients earlier with predictive analytics means it’s possible to take preventative measures before conditions worsen or, sometimes, before they even appear.These statistics and insights demonstrate the significant role of AI in driving the growth of personalized medicine, improving patient outcomes, and revolutionizing healthcare. AI’s ability to analyze vast amounts of data and identify patterns leads to more personalized and effective treatment options for patients.

Focus on Cost-Effectiveness:

With healthcare expenditure on the rise in Japan, there’s a growing emphasis on cost-effective solutions. AI-powered diagnostics present an opportunity for cost savings by reducing the need for repeat tests, minimizing human error in interpretation, and optimizing treatment plans. Additionally, AI contributes to improved preventative measures, leading to lower long-term healthcare costs associated with chronic illnesses.

Market Trends:

Growing Focus on Early Disease Detection and Improved Workflow Efficiency:

The escalating prevalence of chronic diseases like cancer and cardiovascular conditions in Japan underscores the importance of early detection for effective treatment. For instance, as of 2019, approximately 3.1 million individuals in Japan had cancer, and more than 862,000 new cases are diagnosed annually. AI-powered diagnostic tools are positioned to meet this demand by leveraging high-speed data analysis to detect diseases at their incipient stages with remarkable accuracy. By assisting healthcare professionals in identifying subtle abnormalities in medical images and patient data, AI contributes to better treatment outcomes. Furthermore, AI streamlines workflow efficiency by automating repetitive tasks such as image analysis and report generation. This automation not only accelerates diagnostic processes but also allows clinicians to allocate more time to complex cases and patient interaction, ultimately enhancing overall healthcare delivery.

Supportive Government Initiatives and Technological Advancements:

The Japanese government’s proactive support for AI integration in healthcare plays a pivotal role in fostering innovation and adoption. Through funding initiatives and regulatory facilitation, the government creates an enabling environment for the development and deployment of AI-powered medical devices. For example, the Japanese government’s “Society 5.0” program aspires to develop a society that incorporates cutting-edge technology like artificial intelligence (AI) and the Internet of Things (IoT) to improve people’s quality of life. Concurrently, ongoing technological advancements in AI algorithms and machine learning techniques continually enhance the performance and capabilities of diagnostic tools. These advancements enable more nuanced analysis of medical data, leading to heightened accuracy and sensitivity in disease detection. As AI technology progresses, its potential applications in medical diagnostics are poised to expand further, driving sustained market growth and innovation in Japan’s healthcare landscape.

Market Challenges Analysis:

Regulatory Hurdles and Data Privacy Concerns:

The Japanese market for AI-powered medical diagnostics faces significant regulatory challenges, primarily stemming from stringent approval processes. The lengthy timelines associated with regulatory clearance can deter companies from entering the market or delay the introduction of innovative solutions. Moreover, compliance with data privacy regulations, such as the Act on the Protection of Personal Information (APPI), poses additional hurdles. Ensuring robust data security measures and adhering to strict privacy standards can be complex and resource-intensive for companies involved in AI development and training. These regulatory and compliance burdens not only contribute to increased development costs but also impact the pace of market adoption.

Reimbursement Challenges and Physician Adoption:

Limited reimbursement pathways for AI-powered diagnostics in Japan present significant barriers to market growth. The lack of clear financial incentives for hospitals and clinics to invest in these technologies can impede their widespread adoption. Additionally, physician skepticism and integration challenges further hinder market expansion. Healthcare professionals may exhibit reluctance to embrace AI-based diagnostics due to concerns about the technology’s ability to replace their expertise or a lack of understanding of its capabilities. Moreover, seamlessly integrating AI tools into existing clinical workflows within hospitals requires substantial training and infrastructure adjustments, posing additional adoption challenges. Overcoming these reimbursement and adoption barriers will be critical for realizing the full potential of AI-powered medical diagnostics in Japan’s healthcare ecosystem.

Segmentation Analysis:

By Application:

The application of AI in healthcare diagnostics encompasses both in vivo and in vitro diagnostics. In vivo diagnostics involve the analysis of images and data acquired from patients while they are alive, with significant applications across various medical specialties. In radiology, AI aids in the interpretation of medical images such as X-rays, CT scans, and MRIs, facilitating early disease detection and treatment planning. Similarly, in cardiology, AI-powered analysis of electrocardiograms (ECGs) and cardiac imaging modalities enhances the diagnosis of heart conditions like arrhythmias and coronary artery disease. Neurology benefits from AI algorithms analyzing brain scans for early detection of disorders like Alzheimer’s disease and stroke. Other medical specialties, including oncology, orthopedics, and gastroenterology, also leverage AI for image analysis and disease diagnosis. On the other hand, in vitro diagnostics involve the analysis of samples taken from the body, such as blood and tissue, with emerging applications in areas like genomics and pathology. While currently less prominent in the Japanese market, in vitro diagnostics hold potential for growth, particularly in areas such as genomic analysis for disease susceptibility prediction and personalized healthcare approaches.

By End User:

The adoption of AI-powered diagnostic tools spans across various end-users within the healthcare ecosystem. Hospitals and clinics, driven by the need for efficient and accurate diagnostic solutions, constitute the largest user segment. Factors such as increasing patient volumes and the growing burden of chronic diseases contribute to the widespread adoption of AI in these settings. Diagnostic laboratories also leverage AI technologies for automated sample analysis, enhancing workflow efficiency and reducing turnaround times. Furthermore, pharmaceutical and biotechnology companies utilize AI in drug development processes, including target identification, clinical trial design, and drug discovery. Beyond these sectors, other end-users such as research institutions, government agencies, and potentially individual patients utilizing AI-powered self-diagnosis tools represent additional segments contributing to the broader adoption of AI in healthcare.


Based on Component

  • Software
  • Services
  • Hardware
    • Processors
      • MPU
      • GPU
      • FPGA
      • ASIC
    • Memory
    • Networks
      • Adapters
      • Switches
      • Interconnects

Based on Application

  • In Vivo diagnostics
    • By Specialty
      • Radiology
      • Cardiology
      • Neurology
      • Obstetrics/gynecology
      • Ophthalmology
      • Other specialties
    • By Modality
      • Computed tomography
      • X- Ray
      • Magnetic resonance imaging
      • Ultrasound
      • Other modalities
    • In Vitro diagnostics

Based on End User

  • Hospitals
  • Diagnostics Imaging Centers
  • Diagnostics Laboratories
  • Other End User

Regional Analysis:

Kanto Region:

The Kanto region, which includes the Greater Tokyo Area, holds the largest share of the Japan AI in the Medical Diagnostics market, estimated to be around 60%. This region’s dominance can be attributed to several factors, including the presence of major healthcare facilities, research institutions, and a high concentration of technology companies.The Kanto region is home to several renowned medical institutions, such as the University of Tokyo Hospital and the National Cancer Center, which drive the adoption of advanced AI-based diagnostic technologies. Additionally, the region’s thriving technology ecosystem, with companies like Sony, Canon, and Hitachi, has fostered collaboration and innovation in the field of AI for medical diagnostics.

Kansai Region:

The Kansai region, comprising major cities like Osaka, Kyoto, and Kobe, accounts for approximately 25% of the Japan AI in Medical Diagnostics market share. While the demand for AI-based diagnostic solutions in this region has been relatively lower compared to the Kanto region, it is steadily increasing.The Kansai region is characterized by a strong healthcare sector, with several leading medical institutions such as the Osaka University Hospital and the Kyoto Prefectural University of Medicine. The region’s focus on medical research and the adoption of cutting-edge technologies have contributed to the growth of the AI in Medical Diagnostics market.

 Key player:

  • Fujifilm
  • Toshiba
  • IBM Watson Health
  • Siemens Healthineers
  • Philips Healthcare
  • GE Healthcare
  • Google Health
  • NEC Corporation (JPN)
  • Sysmex (JPN)
  • AI Medical Service (JPN)
  • Medmain (JPN)

Competitive Analysis:

Established players like Fujifilm, Toshiba, and NEC Corporation are prominent contributors to the AI-powered medical diagnostics market in Japan. Leveraging their expertise in medical imaging, Fujifilm develops solutions focused on cancer detection and other applications, while Toshiba specializes in medical imaging analysis and diagnostic support systems, particularly in chest X-ray analysis. NEC Corporation also plays a significant role with its AI platforms for medical image analysis and disease prediction, aiming to enhance diagnostic accuracy and efficiency. Despite their strengths, these established players face competition from agile startups dedicated to AI for medical diagnostics. These startups demonstrate nimbleness in developing niche solutions and securing investment for rapid growth. As the market evolves, established players will likely refine their offerings, while startups continue to innovate to address unmet needs, creating a dynamic landscape in the years to come.

Recent Developments:

In September 2023, Mayo Clinic (US) and GE HealthCare (US) collaborated on research and product development programs to better equip clinicians and help diagnose and treat medical conditions.

In February 2023, GE HealthCare to Acquire Caption Health The acquisition adds AI-enabled image guiding to the ultrasound device portfolios of GE HealthCare’s $3 billion Ultrasound division

In January 2023, Intel Corporation (US) launched 4th Gen Intel Xeon Scalable processors (code-named Sapphire Rapids), the Intel Xeon CPU Max Series (code-named Sapphire Rapids HBM) and the Intel Data Center GPU Max Series (code-named Ponte Vecchio), delivering a leap in data center performance, efficiency, security and new capabilities for AI, the cloud, the network and edge, and the world’s most powerful supercomputers.

In December 2022, Riverian and Thynk Health Join Together to Combat Lung Cancer Using Powerful AI and Deep Learning Technology

In November 2022, Google Health reached an agreement with iCAD to commercialize mammography AI.

In October 2022, Google Cloud (US) launched Medical Imaging Suite, a new industry solution that makes imaging healthcare data more accessible, interoperable, and useful. Google Cloud enables the development of AI for imaging to support faster, more precise diagnosis of images, increased productivity for healthcare workers, and improved care access and patient outcomes.

In January 2022, Siemens Healthineers (Germany) and Ohio State Wexner Medical Center (US) partnered to provide cutting-edge imaging and treatment technology to Ohio State patient care, research institutions, and the surrounding regions. The alliance offers cutting-edge radiation oncology and advanced imaging modalities on the Outpatient Care West Campus.

Market Concentration & Characteristics:

The Japan AI in Medical Diagnostics market is currently in a nascent stage, characterized by a mix of established players and emerging companies. Domestic and multinational technology companies are actively participating, with some well-recognized medical device and pharmaceutical firms also entering the fray. This dynamic blend fosters a collaborative environment with ongoing research partnerships and collaborations to accelerate the development and adoption of AI-powered diagnostic tools. This fosters a competitive yet collaborative market landscape expected to evolve significantly as AI integration in medical diagnostics becomes more widespread in Japan.

 Report Coverage:

The research report offers an in-depth analysis based on Technology, Application, End User, and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

  1. AI will play a crucial role in analyzing vast amounts of patient data to personalize treatment plans for lung cancer, breast cancer, and other diseases, leading to more effective therapies.
  2. Advancements in AI-powered image analysis will enable earlier and more accurate detection of diseases like diabetic retinopathy and gastrointestinal cancers, improving patient outcomes.
  3. AI will seamlessly integrate with existing digital pathology workflows, streamlining analysis processes, reducing turnaround times, and enhancing pathologist productivity.
  4. Clinicians will increasingly rely on AI-driven decision support systems that provide real-time insights and recommendations based on patient data, aiding in more informed diagnosis and treatment decisions.
  5. AI in medical diagnostics will extend beyond traditional areas like imaging, venturing into applications like genomics analysis, proteomics exploration, and even drug discovery.
  6. As AI adoption in diagnostics grows, ensuring transparency and explainability of AI-generated results will be paramount to build trust and acceptance among healthcare professionals.
  7. Cloud-based AI solutions will allow smaller hospitals and clinics to access advanced diagnostic tools previously limited to larger institutions, promoting wider access to AI-powered diagnostics.
  8. Synergy between AI developers and medical device companies will lead to the creation of next-generation diagnostic tools with integrated AI functionalities.
  9. Robust data privacy and security measures will be crucial to ensure patient trust and ethical use of patient data in AI-powered diagnostics.
  10. Continued government support through funding, regulatory frameworks, and infrastructure development will foster a conducive environment for the advancement and adoption of AI in medical diagnostics.

For Table OF Content – Request For Sample Report –

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Frequently Asked Questions:

What is the current size of the Japan AI in the Medical Diagnostics market?

The Japan AI in Medical Diagnostics market was valued at USD 97.91 million in 2023.

What factors are driving the growth of the Japan AI in the Medical Diagnostics market?

The growth of the Japan AI in Medical Diagnostics market is primarily driven by factors such as rising demand for early and accurate disease diagnosis, supportive government initiatives and focus on technological innovation, aging population and increasing healthcare needs, technological advancements in AI algorithms and machine learning, and expanding applications in medical diagnostics.

What are the key segments within the Japan AI in Medical Diagnostics market?

The key segments within the Japan AI in Medical Diagnostics market include in vivo diagnostics (such as radiology, cardiology, neurology, and other specialties) and in vitro diagnostics (such as genomics and pathology).

What are some challenges faced by the Japan AI in the Medical Diagnostics market?

Some challenges faced by the Japan AI in the Medical Diagnostics market include regulatory hurdles and data privacy concerns, limited reimbursement pathways, physician skepticism and integration challenges, and the need for addressing radiologist shortages and workload pressures.

Who are the major players in the Japan AI in Medical Diagnostics market?

Major players in the Japan AI in Medical Diagnostics market include Fujifilm, Toshiba, NEC Corporation, and various emerging startups specializing in AI for medical diagnostics.

Which segment is leading the market share?

The in vivo diagnostics segment, particularly applications in radiology, cardiology, and neurology, is leading the market share in the Japan AI in Medical Diagnostics market.

Single Use Upstream Bioprocessing Technology Market

Report ID: 41061

Viral Clearance and Testing Services Market

Report ID: 41070

Rare Kidney Diseases Market

Report ID: 41082

Single Use Bioreactors Market

Report ID: 41087

Oral Solid Dosage Manufacturing Market

Report ID: 41090

Plasmid DNA Manufacturing Market

Report ID: 41100

Nanoparticle Formulation Market

Report ID: 41106

Next Generation Drug Conjugates Market

Report ID: 41115

Lab Automation Market

Report ID: 41013

Sober Living Homes Market

Report ID: 40991

Radiopharmaceuticals Market

Report ID: 40978

Aptamers Therapeutics Technologies and Services Market

Report ID: 40945

Purchase Options

Delivery Format: Excel.
Designed for the individual purchaser.
Users located at a single corporate site or regional office.
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –


+91 6232 49 3207


24/7 Research Support


– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN